Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...

Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl ...

ONAPGO, a subcutaneous infusion device, treats motor fluctuations in advanced Parkinson's disease and launches in the U.S. in 2025. Supernus Pharmaceuticals has announced the FDA approval of ...

FDA OKs New Wearable Infusion Device for Parkinson’sThe FDA has approved Onapgo, a new wearable device for adults with advanced Parkinson’s disease that gives a steady dose of apomorphine ...

1 “ONAPGO represents a novel approach for adults with Parkinson’s disease who are experiencing motor fluctuations,” said Jack Khattar, President and CEO of Supernus Pharmaceuticals.

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer. In a large cohort of ...

Supernus Pharmaceuticals’ Onapgo provides a continuous infusion of apomorphine to manage “off” periods experienced by Parkinson’s disease patients. Approval of Onapgo comes after the FDA ...

ONAPGOis the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease ONAPGO is a wearable subcutaneous ...

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson's disease ONAPGO is a wearable subcutaneous infusion ...